DASH vs REGN
DoorDash, Inc. Class A Common Stock (DASH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DASH and REGN stock pages for the full models.
Not investment advice.